Combination of Local Transcatheter Arterial Chemoembolization and Systemic Anti-angiogenic Therapy for Unresectable Hepatocellular Carcinoma
- 1 January 2012
- journal article
- review article
- Published by S. Karger AG in Liver Cancer
- Vol. 1 (3-4), 201-215
- https://doi.org/10.1159/000343835
Abstract
The pathophysiologic complexity of hepatocellular carcinoma (HCC) and underlying hepatic cirrhosis, make optimal treatment choice a clinical challenge. The radical change in the treatment algorithm of patients with advanced unresectable HCC over the past 7 years, with the introduction of anti-angiogenic agents in patients with only preserved liver function reflect this challenge.Even though data from studies on the combination of transcatheter arterial chemoembolization and anti-angiogenic agents demonstrate a survival advantage in selected patients, this combination is not straightforward. In this review, we’ll examine current data of administering anti-angiogenic therapy in combination with transcatheter arterial chemoembolization and critically evaluate the progress and gaps in current knowledge.Keywords
This publication has 49 references indexed in Scilit:
- Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatmentOncoTargets and Therapy, 2012
- Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 2012
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to SorafenibClinical Cancer Research, 2012
- mTOR Inhibitor for the Treatment of Hepatocellular CarcinomaDigestive Diseases, 2011
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Journal of Clinical Oncology, 2009
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor levelWorld Journal of Gastroenterology, 2004
- Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell UsJNCI Journal of the National Cancer Institute, 2002
- Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.1995